Platinum Priority – Editorial and Reply from Authors
Referring to the article published on pp. x–y of this issue

Do Patients With AR-V7–Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions

By: Emmanuel S. Antonarakisa and Howard I. Scherb

European Urology, Volume 71 Issue 1, January 2017, Pages 4-6

Published online: 01 January 2017

Abstract Full Text Full Text PDF (171 KB)

Refers to article:

Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer

Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, Konrad Steinestel, Martin Boegemann, Andres J. Schrader and Julie Steinestel

Accepted 14 July 2016

January 2017 (Vol. 71, Issue 1, pages 1 - 3)


a Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, MD, USA

b Memorial Sloan Kettering Cancer Center, Sidney Kimmel Center for Prostate and Urologic Cancers, and Weill Cornell Medical College, New York, NY, USA

Corresponding author. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB1–1M45, Baltimore, MD 21287, USA. Tel. +1 443 287 0553; Fax: +1 410 614 8397.

Place a comment

Your comment *

max length: 5000